Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px
Person › Details

Mariola Söhngen (Convert Pharmaceuticals S.A.)

Söhngen, Mariola (Convert Pharmaceuticals 201811– CEO before Mologen + Paion)

 

Organisation Organisation Mologen AG
  Group Mologen (Group)
Product Product  lefitolimod (MGN1703)
     

Mologen AG. (4/20/18). "Press Release: Chief Executive Officer of Mologen AG Will Not Extend Executive Board Mandate Expiring in October 2018 (Ad-hoc News)". Berlin.

The CEO of the biopharmaceutical company MOLOGEN AG, Dr Mariola Soehngen, informed the Supervisory Board that she will not renew her position as member and Chief Executive Officer on the Board of Directors of MOLOGEN AG which expires on 31 October 2018.


The CEO of the biopharmaceutical company MOLOGEN AG, Dr Mariola Soehngen, informed the Supervisory Board that she will not renew her position as member and Chief Executive Officer on the Board of Directors of MOLOGEN AG which expires on 31 October 2018. MOLOGEN AG will immediately begin to look for a suitable successor. During a possible transition period until the appointment of a potential further member and Chairman of the Board of Directors, the remaining members of the Board of Directors will fulfil the tasks of the management to ensure continuity.

- End of ad-hoc notification -


Contact

Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 – 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com


Note about risk for future predictions

Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.

   
Record changed: 2020-02-15

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 650x65px


More documents for Mariola Söhngen


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px




» top